Breaking news

Cyprus’ Kronos Gas Field Moves Closer To Production With $1.8 Billion Deal

by THEFUTURE.TEAM

October 26, 2026

Eni and TotalEnergies have signed contracts worth up to $1.8 billion to develop the infrastructure needed to bring Cyprus’ Kronos natural gas field into production. The agreements mark the start of the project’s implementation phase, with production targeted for the first half of 2028.

The gas will be transported to Egypt for processing and liquefaction before being exported to international markets, primarily Europe. By using existing infrastructure, the project aims to reduce development costs and accelerate the delivery of Cypriot gas to market.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

A Milestone For Cyprus’ Energy Sector

Cyprus President Nikos Christodoulides met an Eni delegation led by Guido Brusco, the company’s chief operating officer for Global Natural Resources, at the Presidential Palace ahead of the contract-signing ceremony. He described the agreements as a vote of confidence in Cyprus’ energy prospects, with significant economic and geopolitical implications.

Brusco called Kronos a historic milestone as the first hydrocarbon field development project in Cyprus. Eni has operated in the country since 2013, and the project follows more than a decade of investment in expertise, personnel and technology. Brusco also highlighted the co-operation between Cyprus, Egypt, Eni and TotalEnergies, stressing that successful delivery will require close co-ordination and rigorous safety standards.

The final investment decision was reached on 28 July 2026, paving the way for the project to move from planning into implementation.

Egypt’s Infrastructure Offers A Route To Market

Located in Block 6 of Cyprus’ Exclusive Economic Zone, the Kronos field is estimated to contain more than 3 trillion cubic feet of natural gas. Once production stabilises, output could reach up to 500 million cubic feet per day, according to Brusco.

Rather than building a new export chain, the project will use existing regional infrastructure. Gas will be transported to Egypt and processed through facilities connected to the Zohr field before being liquefied at the Damietta LNG plant for export.

This approach is central to the project’s commercial strategy. Using existing processing and liquefaction facilities could avoid the cost of developing parallel infrastructure, shorten the route to market and help make the project more economically viable.

International Contractors To Deliver Key Infrastructure

The development involves specialist contractors responsible for subsea systems, pipelines, offshore installation and drilling. Baker Hughes will supply subsea production systems, while Dalmine will undertake pipeline and MEG transfer-related work. TechnipFMC will provide flexible production lines, and McDermott will handle offshore transport, installation, tie-ins and commissioning.

Oceaneering will build the main subsea control cables, while CMHI will construct and install a floating control unit. In Egypt, Petrojet will build a new onshore gas pipeline connecting Zohr with Damietta. Saipem will provide offshore drilling services using its Saipem 10000 drillship.

Together, these contracts cover the main infrastructure required to extract the gas and transport it from the offshore field to Egypt’s processing and export network.

An Emerging Eastern Mediterranean Energy Corridor

Kronos could strengthen energy co-operation across the Eastern Mediterranean by connecting Cyprus’ offshore gas resources with Egypt’s processing and LNG export infrastructure. The project demonstrates how regional partnerships and existing facilities can help bring new energy resources to international markets without requiring every country to build its own complete export system.

For Cyprus, the development offers a path towards becoming a natural gas producer and exporter. Egypt will benefit from the use of its established energy infrastructure, while European markets could gain an additional source of supply at a time of geopolitical uncertainty and heightened concern over energy security.

However, the project’s contribution to Europe will depend on production timelines, export capacity, commercial agreements and market conditions. Kronos is not an automatic replacement for supplies from the United States or Russia, but it could add another source to Europe’s energy mix and support greater diversification.

Other Gas Projects Advance In The Region

Kronos is part of wider efforts to develop the Eastern Mediterranean’s hydrocarbon resources. Chevron continues discussions on the Aphrodite gas field with partners NewMed Energy and Shell. Media reports have also indicated that Shell agreed to sell its stake in Aphrodite to Hungary’s MOL Group, with completion expected in early 2027.

The progress of Kronos and other regional projects will help determine whether Cyprus can turn its offshore discoveries into commercially viable production and become more integrated into regional energy markets. Achieving this will require sustained investment, dependable infrastructure and commercial arrangements that connect gas resources with international buyers.

Closer co-operation between Cyprus and Egypt, alongside wider regional partnerships, will be central to these efforts. If the project meets its production target, Kronos could mark an important step in establishing Cyprus as a contributor to Europe’s energy supply.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.